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ABSTRACT  
In the present research investigation, the utility of employing high dissolving forms of nifedipine for sustained release from matrix tablets with 
almond gum as major release retardant is explored. A poorly soluble BCS class II drug nifedipine is chosen as a model drug. Efforts were made 
to alter the dissolution characteristics of the drug before it is entrapped in the polymer matrix of almond gum. Inclusion complexation in 
sulfobutyl ether beta cyclodextrin or solid dispersion in gelucire (50/13) resulted in enhanced dissolution of nifedipine. The high dissolving 
forms are characterized by x-ray diffraction, differential scanning calorimetry and infra-red spectroscopy. The matrix tablets prepared 
employing the high dissolving forms exhibited satisfactory characteristics such as hardness, friability, swelling index. The drug release is found 
to be slow and spread over a period of 12 hours and the release could be modified with changes in nature of high dissolving form and the 
proportion of almond gum as the major release retardant. Employing high dissolving forms in matrix tablets of almond gum is found to be a 
novel approach in obtaining slow and complete release of poorly soluble drug such as nifedipine.  
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INTRODUCTION  
New technologies and processes are being developed for 
existing and new drug molecules to prepare sustained 
release (SR) and controlled release (CR) dosage forms. SR or 
CR products provide important benefits over the 
conventional immediate release (IR) products [1,2]. These 
include reduced dosing frequency, more favourable plasma 
concentrations and better patient compliance. Most 
approaches in the design of SR dosage forms aim to prepare 
single unit forms such as matrix tablets. For the successful 
development of an SR dosage form, it is essential that the 
technology developed is suitable for the drug involved. 
Biopharmaceutical Classification System (BCS) Class II drugs 
exhibit poor solubility and permeability characteristics [3]. 
The development of SR dosage forms for poorly soluble 
drugs is very challenging.  According to Nixon, the major 
stages involved in drug release from sustained release 
products into the dissolution fluid are: (1) uptake of 
dissolution fluid by the product (2) dissolution of the drug 
substance inside the dosage form and (3) diffusional release 
of drug into the dissolution fluid [4]. The dissolution of the 
drug in the matrix tablet will be crucial for the prompt 
release of the drug. We selected nifedipine as a model drug 
in the present work as it is reported that nifedipine because 
of its crystalline form and slow dissolution shows low drug 
bioavailability [5]. Nifedipine is a calcium channel blocker 
used in the therapy of angina pectoris and it is reported to 
have a biological half-life of 2-3 hours [6]. So employing 
nifedipine as such may not result in prompt release from the 
SR dosage form and the release is likely to be incomplete as 
well. So the main objective of the present work is to increase 
the dissolution rate of nifedipine and employ the high 
dissolving form in the development of sustained release 
matrix tablets using almond gum as the major release 
retardant.  In the present investigation, the dissolution rate 
of nifedipine was increased by employing 2 approaches: i) 
inclusion complexation in sulfobutyl ether beta cyclodextrin 
((SBE7-β-CD) and ii) by solid dispersion (solvent deposited 
system) in gelucire and microcrystalline cellulose.  SBE7-β-
CD is a modified β cyclodextrin that has better drug 
entrapment ability and favourable physical and chemical 
properties than the parent cyclodextrin. It is reported to be 
having high solubility (excess 70 g/100 ml) and minimal 
toxicity. SBE7-β-CD, which is being explored in the 
development of injectable products and found to be useful to 
stabilize drugs, is reported to be safe after intensive chronic 
safety evaluation [7]. Gelucires contain different 
combinations of mono, di and triglycerides which are esters 
of polyethylene glycol and fatty acids. They are inactive 
additives having both hydrophilic and hydrophobic parts. 
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Gelucire 50/13 is a semisolid substance having a hydrophilic 
and lipophilic balance value of 13 and it melts at 500C. Due 
to its affinity for water, it can be considered as a useful 
carrier to prepare fast dissolving products by solid 
dispersion technique [8,9]. In this study, we explored the 
utility of almond gum in the development of sustained 
release matrix tablets. Almond gum is an exudate obtained 
from the plant Amygdalus communis [10]. There are some 
reports on the binding and release retarding properties of 
almond gum and it is reported to be useful in the 
preparation of hydrogel silver nanoparticle [11,12].  
MATERIALS & METHODS 
Nifedipine (gift sample from Julphar Gulf Pharmaceutical 
Industries UAE), sulfobutyl ether beta cyclodextrin (SBE7-β-
CD   - Cydex Corp, USA), Gelucire (50/13) -  Gattefosse, 
France (sample given by Genova Life Sciences, Bengaluru), 
microcrystalline cellulose ( MCC - ), Almond gum is procured 
from Harekrishna Herbals, Kakinada, India. All other 
excipients, chemicals and solvents are of analytical grade 
and were purchased commercially. 
All the experiments with nifedipine were carried out under 
subdued light conditions. 
Inclusion complexation of nifedipine in sulfobutyl ether 
beta cyclodextrin 
Phase solubility study 
Phase solubility studies were done to know the molar ratio 
of complex formation between nifedipine and sulfobutyl 
ether beta cyclodextrin as per Higuchi and Connors method 
[13].  
Excess amounts of nifedipine were added to 15 ml of 
distilled water containing increasing concentrations of SBE7-
β-CD in 25 ml stoppered glass bottles. The resulting 
dispersions were shaken at 370C ± 0.50C for 3 days in a 
temperature controlled shaking water bath (SeichemTech 
SK 330 Pro). At the end of 3 days, a sample dispersion was 
removed and after filtration through a 0.45 μm membrane, 
estimated for nifedipine content by measuring the 
absorbance spectrophotometrically at 238 nm (Shimadzu 
Model UV 1600)  
Phase solubility studies were performed in triplicate. 
Solubility diagram was drawn between the molar 
concentration of nifedipine soluble and the molar 
concentration of SBE7-β-CD. From the resulting plot, the 
stability constant for the formation of complex between 
nifedipine and SBE7-β-CD was determined by employing the 
formula 
 Ks =   Slope / S0 (1 – Slope)           
The slope is calculated from the plot (Fig 1) and S0 is the 
equilibrium solubility of nifedipine. 
Preparation of inclusion complex  
The inclusion complexes of nifedipine with SBE7-β-CD were 
prepared by kneading and freeze-drying procedures in a 1:1 
M ratio. 
Kneading method (KN) 
The required quantities of nifedipine and SBE7-β-CD   were 
accurately weighed, added to a mortar and kneaded for 45 
min. While carrying out the kneading, little quantity of 
methanol: water (20:80 v/v) solution was added to the 
kneaded mass to ensure sufficient consistency. The mass 
obtained was dried at 400C for 48 h, powdered and then 
passed through a 100-mesh sieve, and stored until further 
use. 
Freeze-drying method (FD) 
Appropriate amounts of nifedipine and SBE7-β-CD were 
dissolved in methanol (8 ml) and water (32ml) respectively. 
The aqueous and methonolic solutions were then mixed for 
24 h at 25°C using a magnetic stirrer. The blended solution 
was subjected to freezing at −70°C and latter freeze-dried 
for 48 hrs at −50°C using a freeze-dryer (SP Scientific, Model 
PRO 3XL). The freeze dried powder was sifted through a 
100-mesh sieve and stored until further use. 
Preparation of solvent deposited systems of nifedipine-
gelucire-MCC 
The solid dispersions (solvent deposited systems) of 
nifedipine-gelucire (50/13) were prepared by solvent 
evaporation method. 100 mg of Nifedipine was accurately 
weighed and transferred to a conical flask of 50 ml volume 
and dissolved in 15ml of dichloromethane. Now, 200 mg of 
Gelucire (50/13) is added to this solution and dissolved. In 
this prepared mixture, 700 mg of microcrystalline cellulose 
(MCC) was dispersed and agitated with a magnetic stirrer. 
The solvent was then evaporated under vacuum until a solid 
residue is formed. The obtained mass was then dried under 
a vacuum to get a free-flowing powder. 
Evaluation of inclusion complexes and solvent deposited 
systems 
Dissolution  
The dissolution of nifedipine from pure drug powder, 
solvent deposited system   and the complexes was studied 
using USP Type II dissolution rate test apparatus (Lab India 
Model DISSO).  Nifedipine or the products equivalent to 10 
mg of nifedipine were added to 900 ml of dissolution 
medium (0.1 N hydrochloric acid). The paddle was operated 
at 50 rpm and temperature was maintained at 370C ± 10 C. 
Samples of dissolution medium were removed at various 
time points and after filtration, they were assayed for 
nifedipine dissolved by measuring the absorbance at 238 nm 
employing Shimadzu Model UV 1800 spectrophotometer. 
The findings of dissolution studies are shown in Fig 2 and 
given in Table 1. 
X-ray diffraction  
The powder x - ray diffraction studies of nifedipine and the 
prepared products were done employing X-ray powder 
diffractometer, PANalytical, Model No. X Pert pro employing 
Cu Kα radiation. The diffractograms were obtained between 
2o and 40o at 2 o /min in terms of 2θ angle. A generator 
current of 30 mA at a generator tension (voltage) 40 kV was 
used. The diffractograms of nifedipine and products are 
shown in Fig.3. 
Differential scanning calorimetry (DSC) 
DSC studies were performed to know the physical nature of 
nifedipine in the prepared products and to find out any 
interaction between nifedipine, SBE7-β-CD and gelucire. The 
calorimeter (Shimadzu DSC 60 +) was run at a scanning 
speed of 100C per minute. The temperature range of heating 
was 250C to 3500C. After sealing the samples in aluminium 
pans, heating was carried out in an inert atmosphere which 
is maintained by circulating nitrogen gas. The results of the 
DSC studies are shown in Fig 4. 
Fourier-transform infrared spectroscopy  
The infra-red spectroscopic analysis of nifedipine and the 
products was performed by attenuated total reflectance 
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(ATR) sampling interface technique using Agilent Model 
Cary 630. Different spectra obtained are shown in Fig 5. 
Preparation of matrix tablets employing high dissolving 
forms 
The composition of different matrix tablets is given  in Table 
2. The different excipients are first sieved through sieve 
No.80 to get uniform sized powders. The required quantities 
of various of these powders are taken into a mortar and 
blended uniformly. Little quantities of distilled water were 
added and blended well until sufficient cohesive mass was 
obtained. The mass is now passed through sieve No. 18 and 
the resulting granules are dried at 37C. The dried granules 
are subjected to dry screening by employing sieve No. 35. 
After lubrication, these granules were mixed in a plastic bag 
and then compressed into tablets. 
The flow properties of granules are found out before they 
are compressed. The attributes of various tablets are 
determined. The flow properties of granules and tablet 
characteristics are given  in Tables 3 & 4. 
Determination of swelling index  
The swelling behaviour of matrix tablets was determined at 
370C ± 0.50 C in simulated gastric fluid. Three tablets from 
each formulation were individually kept in a petri dish 
containing 30 ml of the fluid. At the end of six hours the 
tablets are removed, blotted with a tissue paper and 
weighed. The extent of swelling was calculated from the 
formula given below: 
Swelling index = [(Mt - Mo)/Mo] x 100 
where, Mt and Mo are the weights of tablet at time = t and 
time = 0, respectively. 
Drug release studies 
The release of nifedipine from the matrix tablets was 
estimated by utilizing USP Dissolution Rate Test Apparatus 
Type I. Release from different formulations was 
characterized in simulated gastric fluid for first 2 hours and 
in simulated intestinal fluid for the remaining 10 hours. The 
extent of drug release was found out by measuring the 
absorbance (at 238 nm) of release medium samples that are 
removed at regular intervals. 
RESULTS AND DISCUSSION 
Phase solubility study 
The phase solubility diagram of nifedipine as a function of 
the concentration of SBE7-β-CD is shown in Fig 1. The 
amount of nifedipine soluble increased linearly with the 
amount of SBE7-β-CD.  
 
Fig 1: Phase solubility diagrams of nifedipine with SBE7-
β-CD 
The slope of the line was less than one which indicated that 
the complex formed is in 1:1 molar ratio. The stability 
constant of the complex calculated was 262.5 M−1 which 
suggests that the complex will have good stability and 
dissolution required for high bioavailability. Complexes with 
very low or high stability constants are not useful for 
increasing absorption because they are too weak or very 
strong respectively [14]. 
Characterization of inclusion complexes and gelucire 
dispersions 
 Dissolution studies 
The results of the dissolution studies of pure drug nifedipine, 
the inclusion complexes and dispersion in gelucire are 
shown in Fig 2 and given in Table 1. It is observed that the 
complexes and the dispersion exhibited a rapid dissolution 
in comparison to that of the pure drug nifedipine. Out of the 
three fast dissolving forms, the dispersion in gelucire 
showed highest dissolution rate. At the end of 30 minutes, 
the pure drug showed less than 10% dissolution, the 
kneaded and freeze dried complexes exhibited 44% and 
70% dissolution respectively, whereas the dispersion in 
gelucire resulted in 85% dissolution.   To assess the increase 
in dissolution, Khan has suggested the term dissolution 
efficiency (D.E) [15]. Pure nifedipine showed DE30 of 4.16 % 
and the complexes showed 14.12 % (KN) and 28.72 % (FD) 
respectively, whereas the dispersion in gelucire exhibited 
highest DE30 of 40.62%.  The K1 values for the freeze dried & 
kneaded freeze dried complexes and gelucire dispersions 
were higher (0.0218 min-1 & 0.0103 min-1 and 0.0453 min-1) 
compared to pure drug (0.0018 min-1). The extent of 
increase in dissolution observed from the different products 
was assessed by finding out the difference (f1) and similarity 
factors (f2) as per the model proposed by Moore and 
Flanner [16]. The difference factor f1 is proportional to the 
average difference between the two profiles, whereas 
similarity factor f2 is inversely proportional to the average 
squared difference between the two profiles. Generally, if the 
f1 values are above 15 and f2 values are less than 50, then 
the 2 profiles compared are considered as different. In the 
present investigation, when the dissolution profile of pure 
drug is compared with the fast dissolving products the f1 
values are found to be, 77.94, 87.06 & 90.25 and f2 values as 
31.23, 17.91 & 11.89, for kneaded, freeze dried and gelucire 
dispersions respectively suggesting that the increase in 
dissolution observed is significant.  The mechanism of 
increased dissolution is investigated and discussed in detail 
in the sections below.  In case of the gelucire dispersion, the 
presence of microcrystalline cellulose (MCC) on which the 
dispersion is deposited might also have contributed to the 
higher dissolution as deposition on MCC will result in 
significant increase in surface area of the dispersion making 
the product more dispersed in the dissolution medium. 
 
Fig 2 Dissolution profiles of nifedipine, inclusion 
complexes and gelucire dispersion 
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Table 1 Dissolution parameters of fast dissolving products of nifedipine 
Product 
Characteristic * 
Drug Content 
(%) 
T50 
(min) 
D.E 
(%) 
K1  
(min -1)  
[r2] 
Pure drug -- > 60 4.16 ± 0.91 
0.0018 
[ 0.9834] 
FD complex 12.62 ± 0.31 31.1 ± 1.87 28.72 ± 1.25 
0.0218 
[ 0.9885] 
KN complex 12.81 ± 0.29 > 60 14.12 ± 1.37 
0.0103 
[ 0.9921] 
N-Ge-MCC 9.11   ± 0.63 20.1 ± 1.64 40.62 ± 1.19 
0.0453 
[ 0.9955] 
FD – Freeze dried; KN – Kneaded; * Average of 3 determinations 
 
Mechanism of increased dissolution 
To assess the cause of hike in the dissolution rate of 
nifedipine from the prepared products, x-ray diffraction and 
differential scanning calorimetry studies were carried out.  
X - ray diffraction  
The nifedipine inclusion complexes and the solid dispersion 
were evaluated using x-ray diffraction (Fig 3). Pure drug 
nifedipine exhibited sharp diffraction peaks indicating its 
crystalline nature whereas the peaks have significantly 
disappeared in the freeze dried complex and the dispersion 
in gelucire.This indicates that the crystalline drug is 
converted into an amorphous state in these two high 
dissolving products. However, in the case of the complex 
made by kneading method, though there is a reduction in the 
peaks, the diffraction pattern still exhibited a good number of 
peaks. This is probably the reason why the kneaded complex 
showed lesser dissolution rate thanthe freeze dried complex.
 
 
Fig 3  X ray diffractograms  of Nifedipine [A]; Kneaded complex [B]; Freeze dried complex  [C] ; Gelucire dispersion [D] 
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Differential scanning calorimetry 
The endotherms of nifedipine and the high dissolving 
products are shown in Fig 4. The endotherm  
of the pure drug nifedipine showed a sharp peak at 1710C 
which is because of the melting of the drug nifedipine. In 
case of the inclusion complex (FD) and the solid dispersion, 
no melting peak was observed indicating that nifedipine is 
no more in crystalline state but existed in amorphous solid 
solution state in the products. In case of kneaded complex, 
there is a small peak which is broad is observed near the 
melting point of nifedipine. This transformation into 
amorphous form and dispersion of the drug in a finely 
subdivided state explains why in the case of complexes and 
gelucire dispersion, the dissolution of nifedipine is higher 
than that of the pure drug.  
 
 
Fig 4 DSC thermograms of Nifedipine [A]; Freeze dried complex [B]; N-Gelucire dispersion [C] ; Kneaded complex [D]  
 
So the x ray diffraction and differential scanning calorimetric 
studies confirm the existence of nifedipine in amorphous 
state in the freeze dried inclusion complex and the 
dispersion in gelucire, resulting in higher dissolution. The 
order of decreasing dissolution for the 3 different products 
is N-Ge-MCC > freeze dried complex > kneaded complex. 
Fourier-transform infrared spectroscopy  
FTIR spectroscopy (Fig 5) was carried out to detect any 
chemical interaction between nifedipine and the two 
polymers employed to prepare the fast dissolving products. 
Nifedipine exhibited principal IR absorption peaks at 3331 
cm -1 (N-H stretching), 1679 cm -1 (C=O ester), 1625 cm -1 
(C=C aromatic), 1530 cm -1 (NO2) and 1380 cm -1 (-C-CH3) 
[17]. The FTIR spectra of both the inclusion complexes and 
gelucire dispersion contain all the contributions coming 
from nifedipine without exhibiting any dissimilarities. This 
confirms that the drug did not undergo any chemical change 
in the presence of the two polymers in the high dissolving 
forms.  However, in the inclusion complex, the intensity of 
absorption band at 3331 cm -1, due to stretching vibrations 
of the N-H bond in the dihydropyridine ring of nifedipine is 
reduced which could be due to the formation of an inclusion 
complex, this is in agreement with the reported work of 
Mielcarek and Sadaj who observed a similar change upon 
kneading/roll mixing of nifedipine with β-CD in a 1:1 molar 
ratio [18]. There is a small shift in the position of the peak due 
to other potential functional group (C=O), that can be 
involved in the complexation. The peak at 1679 cm-1 has 
slightly broadened and shifted to higher frequencies in the 
inclusion complex. 
 
D 
C 
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Fig 5 FTIR spectra of nifedipine (A); inclusion complex (B); dispersion in gelucire (C) 
 
Preparation and characterization of matrix tablets 
Six different  formulations of matrix tablets were developed 
employing the high dissolving forms and almond gum as the 
major release retardant. The composition of various matrix 
tablets is given  in Table 2. The prepared fast dissolving 
products of nifedipine  (inclusion complex or N-Ge-MCC)  
were mixed with the remaining excipients and wet 
granulated. Wet granulation technique used, is found to be 
suitable and resulted in free flowing granules. The free 
flowing nature of the granules enabled their easy 
compression. The data given in Table 3 suggests satisfactory 
flow nature of granules.The higher angle of repose  values of 
N-Ge-MCC ( inspite of the presence of MCC ) could be due to 
the presence of gelucire as it is waxy in nature and granules 
prepared employing gelucire are usually expected to be less 
free flowing than other formulations. However the Carr’s 
index of all the formulations including the formulation F4 ( 
with N-Ge-MCC ) have exhibited values which are suggestive 
of the flow character that is classified as excellent.
 
Table 2 Composition of different formulations of matrix tablets of nifedipine 
Ingredient (mg) F1 F2 F3 F4 F5 F6 
Nifedipine 20 -- -- -- -- -- 
Inclusion complex 
(FD ) 
-- 110 -- -- -- -- 
Inclusion complex 
(KN ) 
-- -- 110 -- -- -- 
N-Ge-MCC -- -- -- 210 210 210 
Almond gum 100 100 100 100 50 50 
HPMC 50 50 50 50 100 75 
Sodium CMC 50 50 50 50 100 75 
Lactose 260 170 170 70 20 70 
Magnesium stearate 10 10 10 10 10 10 
Talc 10 10 10 10 10 10 
Total weight of each tablet is 500 mg   
 FD – Freeze dried ; KN – Kneaded ; HPMC – Hydroxy propyl methyl cellulose ; N- Nifedipine ; Ge – Gelucire ; MCC – 
Microcyrstalline cellulose ; CMC – Carboxy methyl cellulose 
Table 3   Characteristics of  granules of different formulations 
Formulation 
*Characteristics  
Bulk Density Tapped Density Angle of Repose Carr’s index 
F1 1.310.026 1.380.057 25.490.25 5.070.11 
F2 1.070.026 1.130.049 26.260.49 5.300.12 
F3 1.230.041 1.280.025 25.780.30 3.910.13 
F4 1.170.039 1.270.021 30.740.46 7.870.21 
F5 1.410.017 1.490.017 23.260.39 5.36 0.29 
F6 1.380.024 1.440.024 19.780.17 4.17 0.25 
* Average of 3 determinations 
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Table 4  Characteristics of various matrix tablets 
Formulation 
*Characteristics 
Drug content 
(%) 
Hardness 
(kg/cm2) 
Average weight 
(mg) 
Friability 
(%) 
Swelling 
index (%) 
F1 99.790.21 7.180.20 502.980.29 0.350.61 75.171.21 
F2 99.88  0.14 7.230.11 498.300.67 0.190.07 74.190.91 
F3 100.490.27 7.020.35 501.390.54 0.550.11 75.381.03 
F4 100.260.20 7.460.12 499.890.76 0.440.12 77.971.63 
F5 99.560. 34 7.170.13 502.450.21 0.670.24 59.972.31 
F6 101.330.41 6.890.22 498.670.52 0.730.21 63.971.45 
*  Average of 3 determinations 
 
The various characteristics of compressed tablets were 
determined. The tablets were evaluated with respect to their 
hardness, friability, drug content, weight uniformity and 
swelling index and the respective values are shown in Table 
4. The hardness of tablets of all formulations was in the 
range of  6.89 to 7.46 kg/cm2. The friability of the tablets of 
all the formualtions was less than 1%. The tablet 
formulations in all the prepared batches contained 
nifedipine within 100  5% of expected content. As such, all 
the batches of the  tablets were of good quality with regard 
to hardness, friability and drug content. All tablets are found 
to be uniform in weight with low standard deviation.  
Swelling index study 
In general, the sustained release matrix tablets should not 
disintegrate during the entire length of drug release process. 
During the release, on exposure to the release medium, the 
tablets will  exhibit  swelling and the extent of swelling 
depends on the nature of polymers employed. The presence 
of hydrophilic polymers increases the swelling of the matrix 
tablets. Tablets that exhibit more swelling will have more  
retarding effect on  the drug release. This is because with the 
increase in the swelling, the distrance the drug has to 
transverse to get released will be more. Also the hydrophilic 
polymers that show more swelling, form a gelatinous layer 
around the tablet resultiing in more retarding effect of  drug 
diffusion through the swollen viscous layer [19].  
In the present study, formulations F1 to F4 which  had 
higher amount of almond gum showed more swelling index 
than the formulations F5 and F6 in which the proportion of 
almond gum is reduced and the amounts of HPMC and 
sodium CMC are increased. This could be because of higher 
swelling ability of almond gum compared to HPMC or 
sodium CMC. These differences in swelling index also 
reflected in the different extents of drug release that was 
observed between  F4 and F5 & F6 formulations which 
contained same type of high dissolving form ( the gelucire 
dispersion ) of nifedipine, discussed more in detail below. 
Drug release  
The various drug release profiles are shown in Fig 6. The 
main objective of present study is to evaluate the usefulness 
of employing high dissoving forms of nifedipine in obtaining 
controlled  and  complete release of nifedipine from the 
matrix tablets. This is verified in formulations F1 to F4. In 
case of formulation F1 in which only pure nifedipine was 
used, the drug release is found to be very slow and at the end 
of 12 hours , less than 30% of the drug was released. This is 
because of the poor solubility and dissolution of the drug. 
Whereas in F2 and F3 in which the inclusion complexes 
prepared by kneading and  freeze drying are employed 
respectively, the release is found to be faster. This is because 
of the higher dissolution of nifedipine from  the complexes. 
However it may be also observed that in between the freeze 
dried and kneaded complex, the F3 tablets which had freeze 
dried complex, showed nearly 80% release whereas F2 has 
exhibited only 60% drug release at the end of 12 hours. With 
all the formulation factors remaining constant, this 
difference is only because of the differnce in the extent of 
dissolution oberved between the freeze dried and kneaded 
complexes. But although  in F2 & F3 formulations, the 
release is faster, it is still incomplete at the end of 12 hours.  
Whereas in F4 formulation, which contained the gelucire 
dispersion from which the drug dissolution was highest, has 
shown faster release than F2 & F3 but it is controlled and 
complete at the end of 12 hours. The various drug release 
characteristics are given  in Table 5. 
 
 
 
Fig 6 Drug release profiles of various matrix tablet formulations 
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To know the drug release mechanism, the data are analyzed 
as per first order, Higuchi [20] and Peppas [21] models. The 
model that best fits the release data was evaluated by 
correlation coefficient (r2). The r2 values in various models is 
given in Table 5. When the amount released was plotted 
against square root of time, it gave straight lines with high r2 
values indicating that the drug release is by diffusion. The 
release followed first order kinetics because the correlation 
coefficient values are higher than for the zero order (values 
not shown in the table). The ‘n’ values of Peppas plot ranged 
between 0.5017 and 0.7847 suggesting the release is non-
Fickian anomalous diffusion. Accordingly, the drug release 
from these matrix tablets involves penetration by dissolution 
fluid, dissolution of the drug in dissolution fluid and diffusion 
of the dissolved drug. 
 
Table 5  Drug release characteristics of various nifedipine matrix tablets 
Formulation 
Correlation coefficinet (r2) 
K1 (hr-1) 
KH (mg.hr -
1/2) 
Korsemeyer-
Peppas 
‘ n value’ 
First-
order 
Higuchi 
Korsemeyer-
Peppas 
F1 0.9832 0.9937 0.9934 0.0023 10.38 0.7847 
F2 0.9931 0.9916 0.9919 0.0103 18.72 0.6849 
F3 0.9357 0.9754 0.9862 0.0211 23.05 0.6579 
F4 0.9839 0.9853 0.9941 0.0315 27.14 0.6015 
F5 0.9881 0.9934 0.9872 0.3949 32.84 0.5346 
F6 0.9845 0.9847 0.9581 0.6003 38.63 0.5017 
 
Statistical analysis of drug release profiles  
A statistical analysis is performed to compare the drug 
release profiles of various matrix tablet formulations. 
Analysis of variance (ANOVA) was performed by using two 
factor completely randomized design (CRD) by employing 
MSTATC statistical analysis software. The results of ANOVA 
analysis for products are shown in Table 6. 
According to the results of ANOVA, the percent released was 
found to be highly significantly different at each time level 
(P< 0.001) and among the drug products (P< 0.01), implying 
time with drug product interaction was highly significant (at 
P< 0.01), i.e. that the release profiles were not parallel. This 
interaction indicated that the mean difference of percent 
released among different drug products was not constant at 
any two points of time considered. The calculated F value of 
treatment groups is greater than tabulated F value (at 0.01 
level of probability).  The results of ANOVA showed that the 
drug products were highly significantly different in terms of 
percent released at each time point. 
 
Table 6 Analysis of variance (ANOVA) of the drug release from different formulations 
Source of Data 
Degrees of 
Freedom 
Sum of Squares 
Mean of 
Squares 
F value P 
Time (A) 11 57181.062 5198.28 11802.58 0.000 ** 
Percent Drug Released (B) 5 112412.630 22482.53 51046.11 0.000 ** 
Interaction (AB) 55 7105.413 129.19 293.32 0.000 ** 
Error 144 63.423 0.440   
Total 215 176762.528    
 
CONCLUSION 
From the results of the present investigation, it can be 
concluded that inclusion complexation in sulfobutyl ether 
beta cyclodextrin and dispersion in gelucire gave higher 
dissolution of nifedipine. The higher dissolution is because of 
crystalline nifedipine being converted into amorphous form. 
Compared to the inclusion complexes, nifedipine dispersed 
in gelucire and microcrystalline cellulose gave highest 
dissolution. Sustained release matrix tablets of nifedipine 
could be prepared by using these fast dissolving forms and 
by employing almond gum a major release retardant. The 
release could be modified by changing the type of fast 
dissolving form and proportion of almond gum. The matrix 
tablets prepared by employing gelucire dispersion gave slow 
and complete release. Almond gum is found to be suitable as 
a good release retardant. Employing gelucire dispersions of 
nifedipine and almond gum is a promising new approach to 
obtain the sustained release of poorly water soluble drugs 
such as nifedipine. 
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